| |
Puerto Rico offers top-notch talent, smart tax incentives & a robust supply chain, making it a bioscience powerhouse. With the highest concentration of pharma & medical device talent in the U.S., & extensive tax benefits, it’s the top destination for innovation. Visit our booth at BIO to learn more.
|
|
Today’s Big NewsJun 4, 2024 |
| By Annalee Armstrong Viking Therapeutics is pulling up some extra long boats full of reasons its metabolic dysfunction associated steatohepatitis (MASH) drug could be a winner, but executives were mum on exactly what the med’s future will be given the competitive landscape. |
|
|
|
By Angus Liu Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. |
By Conor Hale The company’s board of directors has approved the plan for Grail to join the Nasdaq, under the ticker “GRAL,” before the end of this month. |
By Ben Adams Hoping to get around the “confusing and painful” journey that patients and carers have when trying to make sense of cancer information, the American Cancer Society and ASCO are teaming up to help build better understanding online under one digital umbrella. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now.
|
|
By Fraiser Kansteiner A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has returned with an endorsement in obesity. However, this time, the organization’s green light has some caveats. |
By Annalee Armstrong Annexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune disorder Guillain-Barré syndrome, meeting the main goal of a phase 3 trial. |
By Conor Hale Researchers at the National Institutes of Health and Memorial Sloan Kettering Cancer Center said their AI tool is built to peruse common and accessible patient information. |
By Andrea Park Biogen is hoping to make the skies a bit more friendly to all airline passengers. |
By Kevin Dunleavy A Portland, Oregon, jury has awarded $260 million to a 49-year-old woman who claimed that more than 30 years of use of Johnson and Johnson's talc products caused her mesothelioma. |
By Gabrielle Masson A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. AbbVie wants to "be part of that wave." |
By Nick Paul Taylor Otsuka and Lundbeck want bipolar I patients to know longer-acting therapies can change their lives. The partners are spreading the message in a multichannel campaign that uses computer-generated imagery (CGI) to show how taking Abilify Asimtufii affected a patient’s summer. |
By Angus Liu In the field of anti-CD38 treatment for multiple myeloma, Johnson & Johnson’s Darzalex casts a long shadow. Now, Sanofi hopes a first-in-class win will help its Sarclisa gain an edge. |
By Helen Floersh While researchers have tried for decades to understand the contribution of the many genes linked to HCM, challenges and inefficiencies around growing heart muscle cells with only specific mutations—and no others that could cloud results—has hampered progress. Until now. |
By Andrea Park With the process of undoing its acquisition of Grail underway, Illumina is making plans for its future without the blood test maker. That involves bringing in a new C-level executive. |
By Helen Floersh The FDA’s “Operation Warp Speed” equivalent for rare disease will include programs from Denali Therapeutics, Neurogene, Larimar Therapeutics and Grace Science, the companies announced June 3 in separate press releases. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," two journalists from the Fierce Biotech team share key insights from their four-part series on the challenges and breakthroughs in cell therapy. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us for a one-hour discussion on oral cyclic peptide drug development. Learn about key breakthroughs that demonstrate results. Register now.
|
|
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
